minor response


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

minor response

In cancer care, a reduction in tumor size by less than 50% but more than 25%.
See also: response
References in periodicals archive ?
Six patients responded to the combination regimen, three of whom achieved a complete response (CR) and three a minor response (MR).
Anti- tumor activity was observed, including evidence of stable disease, minor responses and partial responses reported in one arm of the small cell lung cancer study, and minor and mixed responses and stable disease in the non- small cell lung cancer trial.
Of these, partial responses (PR) were observed in four patients (lung, melanoma (2) and gastric) and minor responses were observed in two patients (thyroid, ovarian), for a total disease control rate (stable disease + partial response + complete response) of 93% in the treated lesions.
Patients with partial and minor responses from the Phase 1 study had refractory tumors including breast, ovaries, cervix, and colon who had failed all prior established treatment regimens, including irinotecan.
Six patients in the study had minor responses (tumor regression by more than 15 percent but less than 30 percent per RECIST, or demonstrated significant cancer biomarker reduction).
Data from a Phase 1 human clinical trial have demonstrated that treatment with ARQ 197 was well tolerated over extended dosing periods, with 60 percent of evaluable patients experiencing partial responses, minor responses or stable disease.
Of 20 evaluable patients, 11 patients benefited from activity, yielding an overall clinical benefit incidence of 55%, including 5 patients with confirmed partial responses, 2 patients with minor responses and 4 patients with extended stable disease.
In the bortezomib-naive group, the overall response rate (complete, partial and minor responses) was 47% (9 out of 19 evaluable patients), including 2 complete responses (CR), 1 near-complete response, 2 partial responses (PR) and 4 minor responses (MR).
In 14 of the 31 patients (45%), there is a clinically beneficial response including one partial response (PR), four minor responses (MR), and nine with stable disease (SD).